Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02)

Bauer, Sebastian; Baier, Hartmut; Baumgärtner, C.; Bohlmann, K.; Fauser, Susanne; Graf, Wolfgang; Hillenbrand, Barbara; Hirsch, M.; Lerche, Holger; Mayer, Thomas; Schulze‐Bonhage, Andreas; Steinhoff, Bernhard J.; Weber, Yvonne G.; Hartlep, Andreas; Rosenow, Felix; Hamer, Hajo M.

doi:10.1016/j.brs.2015.11.003

Cited by 211 publications

(177 citation statements)

References 16 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…There have been several studies exploring the behavioral or therapeutic effects of taVNS, many of which are positive [38–41]. The extant literature suggests that tragus stimulation directly modulates the vagus network via the ABVN.…”

Section: Discussionmentioning

confidence: 99%

Short trains of transcutaneous auricular vagus nerve stimulation (taVNS) have parameter-specific effects on heart rate

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Short trains of transcutaneous auricular vagus nerve stimulation (taVNS) have parameter-specific effects on heart rate

et al. 2018

View full text Add to dashboard Cite

show abstract

“…By the end of the treatment, mean seizure reduction was 2.9 % in the 1 Hz group and 23.4 % in the 25 Hz group with mild adverse effects. Superiority of 25 Hz tVNS over 1 Hz tVNS could not be proven in this study but efficacy data revealed results that justify further trials with larger patient numbers with longer observation periods [76] .…”

Section: Other Methodsmentioning

confidence: 79%

An Overview of Non-drug Therapies for the Treatment of Epilepsy

Yasam¹,

Jakki²,

Senthil³

et al. 2018

pharmaceutical-sciences

View full text Add to dashboard Cite

Yasam, et al.: Epilepsy and Non-drug TherapiesEpilepsy is one of the most common neurological disorders, characterized by recurrent spontaneous seizures and a major health problem that affects around 1-2 % of the population worldwide. The treatment generally includes antiepileptic drug therapies. However, despite the development of various antiepileptic drugs, about a third of patients are resistant to current pharmacotherapies. Non-drug therapies are also expanding in an exciting and unprecedented way since in patients with drug resistance, non-drug therapies like surgeries; implantable devices and diet are playing a key role in improving the quality of patient's life. In this review, the current available non-drug therapies ranging from preclinical to clinical for controlling seizures in epileptic patients with drug resistance have been highlighted. Initial results from these therapies are quite promising, but considerable development is required before these treatments earn a place in the standard clinical care.

show abstract

“…Therefore, compared with VNS, transcutaneous vagus nerve stimulation (ta‐VNS) has many advantages, including noninvasive, price moderate, fewer side effects. Many clinical trials have proved that ta‐VNS has a similar therapeutic effect with VNS . Frangos et al done research that 13 healthy subjects accept cutaneous electrical stimulation to the right anterolateral surface of the neck during fMRI scanning .…”

Section: Safety and Complicationsmentioning

confidence: 99%

Research progress of vagus nerve stimulation in the treatment of epilepsy

Fan

Shan

et al. 2019

CNS Neurosci Ther

View full text Add to dashboard Cite

The International League Against Epilepsy (ILAE) defined drug‐resistant epilepsy (DRE) that epilepsy seizure symptoms cannot be controlled with two well‐tolerated and appropriately chosen antiepileptic drugs, whether they are given as monotherapy or in combination. According to the WHO reports, there is about 30%‐40% of epilepsy patients belong to DRE. These patients need some treatments other than drugs, such as epilepsy surgery, and neuromodulation treatment. Traditional surgical approaches may be limited by the patient's clinical status, pathological tissue location, or overall prognosis. Thus, neuromodulation is an alternative choice to control their symptoms. Vagus nerve stimulation (VNS) is one of the neuromodulation methods clinically, which have been approved by the Food and Drug Administration (FDA). In this review, we systematically describe the clinical application, clinical effects, possible antiepileptic mechanisms, and future research directions of VNS for epilepsy.

show abstract

Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02)

Cited by 211 publications

References 16 publications

Short trains of transcutaneous auricular vagus nerve stimulation (taVNS) have parameter-specific effects on heart rate

Short trains of transcutaneous auricular vagus nerve stimulation (taVNS) have parameter-specific effects on heart rate

An Overview of Non-drug Therapies for the Treatment of Epilepsy

Research progress of vagus nerve stimulation in the treatment of epilepsy

Contact Info

Product

Resources

About